EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted gene therapy alleviates epilepsy and hyperexcitability in models of SCN2A deficiency

Zaiyang Zhang, Jingliang Zhang, Xiaoling Chen, Brody A Deming, Shivam Kant, Purba Mandal, Harish Kothandaraman, Phillip J SanMiguel, Manasi S Halurkar, Akila D Abeyaratna, Morgan J Robinson, Iuliia Vitko und 9 weitere

Journal of Clinical Investigation · 03.11.2026

DOI: 10.1172/jci196068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.11.2026. Verfasst von Zaiyang Zhang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Borch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, United States of America. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathogenic SCN2A loss-of-function (LoF) variants can cause severe, refractory epilepsy with limited treatment options. Existing Scn2a -LoF mouse models exhibit few spontaneous seizures, limiting the dynamic range needed to assess therapeutic efficacy. We therefore generated gene-trap Scn2a -deficient mice on the seizure-prone DBA/2J background. These mice experienced hundreds of spontaneous absence seizures per day, characterized by concurrent behavioral arrest and EEG spike–wave discharges (SWDs). Partial restoration of Scn2a expression reduced seizure burden. Electrophysiological analysis revealed impaired action potential waveforms yet increased repetitive firing, alongside coordinated downregulation of voltage-gated potassium channel genes, potentially contributing to hyperexcitability. Given the broad potassium channel downregulation and prior efficacy of KCNA1 gene therapy in refractory seizure models, we selected KV1.1 as a potential therapeutic target and used a drug-controllable adeno-associated virus (AAV) to express human KCNA1 . We found that this intervention normalized elevated neuronal firing and reduced spontaneous seizure burden in Scn2a -deficient mice. Extending these findings to a human cell-based platform, AAV-mediated KCNA1 expression also reduced neuronal firing in human cortical organoids carrying a SCN2A -truncating variant identified in patients. Together, these findings provide proof of principle for drug-controllable KCNA1 gene therapy as a promising treatment avenue for epilepsy related to SCN2A LoF variants.

Schlagwörter

Stichwörter der Autor:innen

Cell biologyEpilepsyGene therapyHuman stem cellsNeuroscience

Autor:innen und Institutionen

  • Borch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, United States of America.
  • Purdue Institute for Cancer Research, Purdue University, West Lafayette, United States of America.
  • Purdue Genomics Core, Bindley Bioscience Center, Purdue University, West Lafayette, United States of America.
  • University of Virginia School of Medicine, Charlottesville, United States of America.
  • Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, United States of America.
  • Department of Genetic and Cellular Medicine, University of Massachusetts Chan Medical School, Worcester, United States of America.

Förderung

  • The National Institute of Neurological Disorders and Stroke

Zitieren

APA

Zhang, Z., Zhang, J., Chen, X., Deming, B. A., Kant, S., Mandal, P., Kothandaraman, H., SanMiguel, P. J., Halurkar, M. S., Abeyaratna, A. D., Robinson, M. J., Vitko, I., Gaykema, R. P., Yuan, C., Lanman, N. A., Tegtmeyer, M. T., Wang, D., Gao, G., Shi, R., …, & Yang, Y. (2026). Targeted gene therapy alleviates epilepsy and hyperexcitability in models of SCN2A deficiency. Journal of Clinical Investigation. https://doi.org/10.1172/jci196068

Vancouver

Zhang Z, Zhang J, Chen X, Deming BA, Kant S, Mandal P, et al. Targeted gene therapy alleviates epilepsy and hyperexcitability in models of SCN2A deficiency. Journal of Clinical Investigation. 2026. doi:10.1172/jci196068

BibTeX
@article{Zhang2026,
  author = {Zhang, Zaiyang and Zhang, Jingliang and Chen, Xiaoling and Deming, Brody A and Kant, Shivam and Mandal, Purba and Kothandaraman, Harish and SanMiguel, Phillip J and Halurkar, Manasi S and Abeyaratna, Akila D and Robinson, Morgan J and Vitko, Iuliia and Gaykema, Ronald P and Yuan, Chongli and Lanman, Nadia A and Tegtmeyer, Matthew T and Wang, Dan and Gao, Guangping and Shi, Riyi and Perez-Reyes, Edward and Yang, Yang},
  title = {Targeted gene therapy alleviates epilepsy and hyperexcitability in models of SCN2A deficiency},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci196068}
}
Kostenlos starten →